Primary or secondary prevention of HIV-associated histoplasmosis during the early antiretrovirals for all era

PLoS Negl Trop Dis. 2023 Feb 2;17(2):e0011066. doi: 10.1371/journal.pntd.0011066. eCollection 2023 Feb.
No abstract available

MeSH terms

  • AIDS-Related Opportunistic Infections*
  • Anti-Retroviral Agents / therapeutic use
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Histoplasmosis* / complications
  • Histoplasmosis* / drug therapy
  • Histoplasmosis* / prevention & control
  • Humans
  • Secondary Prevention

Substances

  • Anti-Retroviral Agents

Grants and funding

The authors received no specific funding for this work.